Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome

Diabetes and Vascular Disease Research

Volumn 8, Issue 4, 2011, Pages 262-270

  Averna, Maurizio ^a   Missault, Luc ^b   Vaverkova, Helena ^c   Farnier, Michel ^d   Viigimaa, Margus ^e   Dong, Qian ^f   Shah, Arvind ^f   Johnson Levonas, Amy O ^f   Taggart, William ^f   Brudi, Philippe ^f  

^a UNIVERSITY OF PALERMO   (Italy)

^b General Hospital St Jan   (Belgium)

^c UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^d Point Medical   (France)

^e TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

cholesterol; ezetimibe; hypercholesterolaemia; lipid; metabolic syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GALLBLADDER DISEASE; GASTROINTESTINAL SYMPTOM; HEPATITIS; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; MULTICENTER STUDY; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT DURATION;

AGED; ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; AZETIDINES; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY DISEASE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG SUBSTITUTION; EUROPE; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LEAST-SQUARES ANALYSIS; LIPIDS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; PYRIMIDINES; RISK ASSESSMENT; RISK FACTORS; SIMVASTATIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 80053091278     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164111418136     Document Type: Article

References (24)

1. Ford E, Giles W, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002 ; 287: 356-359 (Pubitemid 34251969)
2. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004 ; 27: 2444-2449 (Pubitemid 39281399)
3. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 ; 120: 1640-1645
4. Expert Panel on Detection EaToHBCiA. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497
5. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004 ; 44: 720-732
6. Sweeney ME, Johnson RR. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Exp Opin Drug Metab Toxicol. 2007 ; 3: 441-450 (Pubitemid 47316034)
7. Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2004 ; 26: 1758-1773 (Pubitemid 40089489)
8. Simons L, Tonkon M, Masana L, Maccubbin D, Shsh A, Lee M, et al. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin. 2004 ; 20: 1437-1445 (Pubitemid 39361347)
9. Abate N, Catapano AL, Ballantyne CM, Davidson MH, Polis A, Smugar SS, et al. Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: results of two subgroup analyses. J Clin Lipid. 2008 ; 2: 91-105 (Pubitemid 351372954)
10. Conard S, Bays H, Bird S, Leiter LA, Lin J, Hanson ME, et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab. 2010 ; 12: 210-218
11. Feldman T, Zakson-Aiken M, Shah A, Maccubbin D, Tribble D, Veltri E, et al. Effect of ezetimibe/simvastatin (EZE/SIM) versus SIM monotherapy on the lipid profile of hypercholesterolemic (HC) patients with metabolic syndrome (MetS). Diabetes. 2005 ; 54: A148
12. Gil-Extremera B, Mendez G, Zakson M, Meehan A, Shah A, Lin J, et al. Efficacy and safety of ezetimibe/simvastatin co-administered with fenofibrate in mixed hyperlipidemic patients with metabolic syndrome. Metab Syndr Relat Disord. 2007 ; 5: 305-314 (Pubitemid 350208898)
13. Ishwarlal J, Devaraj S. Statin therapy for the metabolic syndrome: the evidence base. Metab Syndr Relat Disord. 2009 ; 7: 393-395
14. Polis AB, Abate N, Catapano AL, Ballantyne CM, Davidson MH, Smugar SS, et al. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009 ; 7: 601-610
15. Robinson JG, Ballantyne CM, Grundy SM, Hsueh WA, Parving HH, Rosen JB, et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET Study). Am J Cardiol. 2009 ; 103: 1694-1702
16. Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome. Diabetes Care. 2009 ; 32: 1087-1091
17. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008 ; 51: 1512-1524 (Pubitemid 351470037)
18. Farnier M, Averna M, Missault L, Vaverkova H, Massaad R, Vandormael K, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy-The IN-CROSS study. Int J Clin Pract. 2009 ; 63: 547-559
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972 ; 18: 499-502
20. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes. 2010 ; 59: 1153-1160
21. Watts GF, Ooi EMM, Chan DC. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo. Pharmacol Ther. 2009 ; 123: 281-291
22. Chan DC, Barrett HR, Watts GF. Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies. Clin Biochem Rev. 2004 ; 25: 31-48
23. Sniderman AD. Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm. Curr Opin Lipidol. 2004 ; 15: 433-438 (Pubitemid 39061623)
24. Sniderman AD, de Graaf J, Couture P, Williams K, Kiss RS, Watts GF. Regulation of plasma LDL: the apoB paradigm. Clin Sci. 2010 ; 118: 333-339